Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seclidemstat and Pembrolizumab in SWI/SNF-mutant Gynecologic Cancers
NCT04611139Phase 1Withdrawn
- Sponsor
- HonorHealth Research Institute
- Start
- Dec 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of Seclidemstat in Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT), ovarian clear cell carcinoma (OCCC), ovarian endometrioid adenocarcinoma and 1 more, sponsored by HonorHealth Research Institute. Primary endpoint: Incidence of Adverse Events. Planned start Dec 2021; status: withdrawn.
02
Drugs
Seclidemstat
03
Conditions
Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT)ovarian clear cell carcinoma (OCCC)ovarian endometrioid adenocarcinomaendometrial cancer (EC)
Beyond the preview
Go deeper on NCT04611139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04611139.